This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Catherine Day" biochemist – news · newspapers · books · scholar · JSTOR (January 2024) (Learn how and when to remove this template message)

Catherine Day
Day in 2012
Alma materMassey University
Scientific career
Thesis

Catherine Louise Day is a New Zealand biochemist. She is currently a professor and was the head of the biochemistry department at the University of Otago.[1]

Career

After a BSc at Massey University, Day completed a PhD entitled Expression and characterisation of the n-terminal half of human lactoferrin in 1993,[2] also at Massey, before moving to the University of Otago where she rose to professor and head of department.[1]

She has received funding from the Health Research Council of New Zealand[3] and Genesis Oncology Trust[4] and is an associate editor for biochemistry and biophysics of the Royal Society's Open Science Journal.[5]

Selected works

References

  1. ^ a b "Profile, Department of Biochemistry, University of Otago, New Zealand". Otago.ac.nz. Retrieved 16 December 2017.
  2. ^ Day, Catherine (1993). Expression and characterisation of the n-terminal half of human lactoferrin (Doctoral thesis). Massey Research Online, Massey University. hdl:10179/4125.
  3. ^ "Professor Catherine Day | Health Research Council". Hrc.govt.nz. Retrieved 16 December 2017.
  4. ^ "Monday 4 December 2017, Otago researchers gain new insights into inflammatory signalling mechanisms implicated in cancer, News and events, Department of Biochemistry, University of Otago, New Zealand". Otago.ac.nz. 4 December 2017. Retrieved 16 December 2017.
  5. ^ "Biochemistry and Biophysics | Open Science". Rsos.royalsocietypublishing.org. Archived from the original on 16 December 2017. Retrieved 16 December 2017.
  6. ^ Chen, Lin; Willis, Simon N.; Wei, Andrew; Smith, Brian J.; Fletcher, Jamie I.; Hinds, Mark G.; Colman, Peter M.; Day, Catherine L.; Adams, Jerry M.; Huang, David C. S. (4 February 2005). "Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function". Molecular Cell. 17 (3): 393–403. doi:10.1016/j.molcel.2004.12.030. ISSN 1097-2765. PMID 15694340.
  7. ^ van Delft, Mark F.; Wei, Andrew H.; Mason, Kylie D.; Vandenberg, Cassandra J.; Chen, Lin; Czabotar, Peter E.; Willis, Simon N.; Scott, Clare L.; Day, Catherine L.; Cory, Suzanne; Adams, Jerry M. (November 2006). "The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized". Cancer Cell. 10 (5): 389–399. doi:10.1016/j.ccr.2006.08.027. ISSN 1535-6108. PMC 2953559. PMID 17097561.
  8. ^ Verhagen, Anne M.; Silke, John; Ekert, Paul G.; Pakusch, Miha; Kaufmann, Hitto; Connolly, Lisa M.; Day, Catherine L.; Tikoo, Anjali; Burke, Richard; Wrobel, Carolyn; Moritz, Robert L. (4 January 2002). "HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins". The Journal of Biological Chemistry. 277 (1): 445–454. doi:10.1074/jbc.M109891200. ISSN 0021-9258. PMID 11604410.
  9. ^ Czabotar, Peter E.; Lee, Erinna F.; van Delft, Mark F.; Day, Catherine L.; Smith, Brian J.; Huang, David C. S.; Fairlie, W. Douglas; Hinds, Mark G.; Colman, Peter M. (10 April 2007). "Structural insights into the degradation of Mcl-1 induced by BH3 domains". Proceedings of the National Academy of Sciences of the United States of America. 104 (15): 6217–6222. Bibcode:2007PNAS..104.6217C. doi:10.1073/pnas.0701297104. ISSN 0027-8424. PMC 1851040. PMID 17389404.

External links

Authority control databases: Academics
Categories